Mechanisms and anatomical risk factors of pneumothorax after Bevacizumab use: A case report

BACKGROUND: Bevacizumab is an antiangiogenic agent, and that synergizes with chemotherapeutic drugs. When used in combination therapies, Bevacizumab is associated with adverse events such as hemorrhage, gastrointestinal perforation, delayed wound healing, and pneumothorax. However, the molecular mec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:World J Clin Oncol
Hauptverfasser: Ozaki, Yuri, Yoshimura, Akiyo, Sawaki, Masataka, Hattori, Masaya, Gondo, Naomi, Kotani, Haruru, Adachi, Yayoi, Kataoka, Ayumi, Sugino, Kayoko, Horisawa, Nanae, Endo, Yuka, Nozawa, Kazuki, Sakamoto, Shoko, Iwata, Hiroji
Format: Artigo
Sprache:Inglês
Veröffentlicht: Baishideng Publishing Group Inc 2020
Schlagworte:
Case Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7407928/
https://ncbi.nlm.nih.gov/pubmed/32821655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5306/wjco.v11.i7.504
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge